What's new

Opinion/decision on a Paediatric investigation plan (PIP): Vabysmo, Faricimab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Eye disorders, PIP number: P/0006/2024

Opinion/decision on a Paediatric investigation plan (PIP): Vabysmo, Faricimab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Eye disorders, PIP number: P/0006/2024

Mar 17, 2025 - 15:10
 0
Opinion/decision on a Paediatric investigation plan (PIP): Vabysmo, Faricimab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Eye disorders, PIP number: P/0006/2024
Opinion/decision on a Paediatric investigation plan (PIP): Vabysmo, Faricimab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Eye disorders, PIP number: P/0006/2024
Read More

Tags:

Previous Article

AstraZeneca adds ‘in vivo’ cell therapy capabilities with EsoBiotech deal

Next Article

PepsiCo to acquire poppi

Related Posts

Questions and answers for biological medicinal products

Questions and answers for biological medicinal products

Feb 25, 2025  0

Human medicines European public assessment report (EPAR): Obgemsa, vibegron, Date of authorisation: 27/06/2024, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 19, 2025  0

Human medicines European public assessment report (EPAR): Ituxredi, rituximab, Date of authorisation: 19/09/2024, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 10, 2025  0